Suven Life Sciences gets patent for neuro-degenerative drug
New Delhi: Drug firm Suven Life Sciences has been granted a patent each by Eurasia, Europe, Israel and Macau for a drug used in the treatment of neuro-degenerative diseases.
"The grant of one product patent from Eurasia, one product patent from Europe, one product patent from Israel and one product patent from Macau corresponding to the New Chemical Entities for the treatment of disorders associated with Neuro-degenerative diseases," Suven Life said in a BSE filing.
The patents are valid till 2030, the company added.
Suven Life CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."
With these new patents, Suven has a total of 15 granted patents from Eurasia, 18 from Europe, 8 from Israel and 5 from Macau.
"These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II," Suven said.
"The grant of one product patent from Eurasia, one product patent from Europe, one product patent from Israel and one product patent from Macau corresponding to the New Chemical Entities for the treatment of disorders associated with Neuro-degenerative diseases," Suven Life said in a BSE filing.
The patents are valid till 2030, the company added.
Suven Life CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."
With these new patents, Suven has a total of 15 granted patents from Eurasia, 18 from Europe, 8 from Israel and 5 from Macau.
"These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II," Suven said.
Next Story